About NimbleGen
NimbleGen is a company based in Basel (Switzerland) founded in 1999 was acquired by Roche in June 2007. NimbleGen has raised $31.39 million across 5 funding rounds from investors including Roche, NIH and Baird. NimbleGen operates in a competitive market with competitors including Abcam, Stem Cell Technologies, GenScript, Sino Biological and RareCyte, among others.
- Headquarter Basel, Switzerland
- SectorsHealthcare
- Website nimblegen.com
- Social LinkedIn X Facebook
- Acquired by Roche (Jun 2007)
Funding Insights of NimbleGen
NimbleGen has successfully raised a total of $31.39M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $415 thousand completed in July 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.39M
- Total Rounds 5
- Last Round Grant — $415,000
- First Round $500,000
(Jun 2001)
- Investors Count 10
All 5 funding rounds of NimbleGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2007 | $415,000 | Grant | – | – | |
| Jan 2007 | $12.5M | Series C | – | – | – |
| Dec 2005 | $8.39M | Series B | – | Cargill Ventures, Skyline Ventures | |
| Sep 2001 | $10.5M | Series A | – | – | |
| Jun 2001 | $500,000 | Debt – Conventional | – | – |
11 investors in total: 11 institutional.
Investors in NimbleGen
NimbleGen has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, NIH and Baird.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on information technology, life sciences, and clean technology sectors | – | cargillventures.com | San Mateo, United States | |
US life sciences companies are invested in by Skyline Ventures. | – | skylineventures.com | Palo Alto, United States | |
- | – | topspinventure.com | - | |
Multiple sectors focused seed & early stage VC firm investing in the US, Europe & Asia | – | ventureinvestors.com | Madison, United States | |
Global private equity and venture capital investments in B2B Tech & Services companies. | – | bairdcapital.com | - | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Financial services including wealth management and investment banking are offered by Baird. | 1919 | rwbaird.com | Milwaukee, United States | |
- | – | swib.state.wi.us | - | |
Research innovations are supported and commercialized by WARF. | – | warf.org | Madison, United States | |
Government entity focused on electronic safety and licensing application | – | commerce.wi.gov | United States |
Investor details for NimbleGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of NimbleGen
4 dated milestones of NimbleGen across 8 years, from founding to its latest funding, stage changes and deals.
- Founded NimbleGen is founded.
- Funding First funding round of $500K.
- Exit Acquired by Roche.
- Funding Latest funding round, Grant, of $415K.
Competitors of NimbleGen
NimbleGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, GenScript, Sino Biological and RareCyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| sinobiological.com | 2007 | Beijing, China | $29.41M | – | Reagents and kits are provided for clinical research applications. | |
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. | |
| seqwell.com | 2014 | Beverly, United States | $24.51M | 30 | NGS-based reagents and kits are supplied for life sciences research. | |
| miltenyibiotec.com | 1989 | Bergisch Gladbach, Germany | – | 585 | Develops tools and products for research and clinical application | |
| devyser.com | 2004 | Stockholm, Sweden | $15.48M | – | Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders | |
| paragongenomics.com | 2015 | San Francisco, United States | $8M | 26 | Provider of technologies and solutions genomic research and precision medicine |
Detailed competitors of NimbleGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NimbleGen
Websites that share an audience with NimbleGen (nimblegen.com).
Websites whose visitors overlap most with NimbleGen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| affymetrix.com | 100% | 1.1K | #9,164,392 | View details | |
| illumina.com | 100% | 672.7K | #61,793 | View details | |
lifescience.roche.com | lifescience.roche.com | 88% | – | – | – |
promega.com | promega.com | 85% | – | #192,389 | – |
| appliedbiosystems.com | 83% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 27 similar websites and full traffic analytics for NimbleGen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 27 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to NimbleGen
10 companies that operate in the same segment as NimbleGen (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NimbleGen
NimbleGen was founded in 1999 and raised its 1st funding round 2 years after it was founded.
NimbleGen is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
NimbleGen is a funded company, having raised a total of $31.39M across 5 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $500K, raised on Jun 2001.
NimbleGen Systems was a life sciences company focussed on developing solutions for genomics research. They used their proprietary Maskless Array Synthesis technologies to manufacture their suite of microarray products that included the microarray instruments, reagents as well as off-the-shelf and custom microarrays. It leveraged its expertise in genomics to develop reagents and kits for targeted next generation sequencing. In June 2007, Roche acquired NimbleGen for 272.5M. Currently, NimbleGens targeted NGS library preparation reagents and kits are available under the NimbleGen SeqCap range from Roche.
NimbleGen's top competitors include Abcam, Sino Biological and Paragon Genomics.
NimbleGen has 11 investors. Key investors include Roche, NIH, Baird, Wisconsin Department of Commerce, and Cargill Ventures.
Yes. NimbleGen was acquired by Roche in June 2007.